Evommune, Inc. Announces Phase 2a Data Presentation at EADV Congress

What Happened
Evommune, Inc. (EVMN) filed a Form 8‑K on October 1, 2026 (Item 7.01) to disclose a press release announcing that the company is presenting late‑breaking Phase 2a proof‑of‑concept data for its EVO301 program in atopic dermatitis at the European Academy of Dermatology and Venereology (EADV) Congress. The press release is furnished as Exhibit 99.1 to the filing. The report was signed by Luis Peña, President and Chief Executive Officer.

Key Details

• Filing date: October 1, 2026 (Form 8‑K, Item 7.01 — Regulation FD Disclosure).
• Event: Presentation of late‑breaking Phase 2a proof‑of‑concept data for EVO301 in atopic dermatitis at the EADV Congress.
• Exhibit: Press release titled "Evommune Presents Late‑Breaking Phase 2a Proof‑of‑Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress" included as Exhibit 99.1.
• Signatory: Luis Peña, President and CEO, executed the filing on behalf of Evommune.

Why It Matters
A late‑breaking Phase 2a presentation is a concrete clinical development that provides new, company‑issued data about EVO301 and its potential in atopic dermatitis. For investors, this update is a near‑term informational event: the press release and presentation may contain efficacy, safety, or enrollment details that affect how the market values Evommune’s clinical program. Retail investors should read the furnished press release (Exhibit 99.1) and monitor follow‑up disclosures for any specific data, changes to development timelines, or planned next steps.